NGLFINE · Healthcare · Drug Manufacturers - General
Composite scorecard: 52/100 — Quality 53 · Valuation 21 · Momentum 100
| Share price | ₹3,010.00 |
| Market cap | ₹1,973 Cr |
| P/E ratio | 41.0 |
| P/B ratio | 6.0 |
| ROCE | 17.2% |
| Dividend yield | 0.05% |
| Book value | ₹532.95 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹501 Cr | ₹48 Cr | 15.0% |
| 2025 | ₹368 Cr | ₹21 Cr | 9.0% |
| 2024 | ₹339 Cr | ₹41 Cr | 16.0% |
| 2023 | ₹278 Cr | ₹20 Cr | 13.0% |
| 2022 | ₹318 Cr | ₹50 Cr | 21.0% |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunix